Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The goal of Part I of this clinical research study is to find the highest tolerable dose of
TPI 287 that can be given with bevacizumab to patients with glioblastoma. The goal of Part II
is to learn if TPI 287 when given with bevacizumab can help to control glioblastoma better
than when bevacizumab is given alone. The safety of the drug combination will also be
studied.
TPI 287 is similar to a type of chemotherapy drug called a taxane and is designed to block a
protein (tubulin) that helps the cancer cells divide. By blocking the tubulin, the drug may
be able to cause the cancer cells to shrink or stop growing.
Bevacizumab is designed to prevent or slow down the growth of cancer cells by blocking the
growth of blood vessels.